Quantitative Stress Echocardiography to Diagnose Myocardial Ischaemia (DEVISE)

September 2, 2018 updated by: Professor Alan G Fraser, University Hospital of Wales

Development, Validation and Implementation of a New Quantitative Stress Echocardiographic Test for Myocardial Ischaemia

Patients with chest pain on exertion need a reliable non-invasive test to identify if they have inducible myocardial ischaemia. This would reduce the use of diagnostic coronary arteriography, avoid its risks and costs, and guide clinical decisions. Conventional stress echocardiography has poor reproducibility because it relies on qualitative and subjective interpretation. Quantitative approaches based on precise and reliable measurements of myocardial velocity, strain, strain rate and global longitudinal strain have been shown to be able to accurately diagnose myocardial ischaemia. A more accurate test using myocardial velocity imaging was not implemented by ultrasound vendors although it provided an objective measurement of myocardial functional reserve on a continuous scale from normality to severe ischaemia.

The investigators propose an original approach to create a diagnostic software tool that can be used in routine clinical practice. The investigators will extract and compare quantitative data obtained through myocardial velocity imaging and speckle tracking in subjects who undergo dobutamine stress echocardiography.

The data will be analysed using advanced computational mathematics including multiple kernel learning and joint statistics applied to multivariate data across multiple dimensions (including velocity, strain and strain rate traces). This approach will be validated against quantitative coronary arteriography and fractional flow reserve. The results will be displayed as parametric images and placed into a reporting tool. The output will determine the presence and severity of myocardial ischaemia. These new tools will have the capacity for iterative learning so that the precision of the diagnostic conclusions can be continuously refined.

Study Overview

Status

Unknown

Study Type

Observational

Enrollment (Anticipated)

390

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Alan G Fraser

Study Locations

      • Leuven, Belgium
        • Not yet recruiting
        • UZ Leuven
        • Contact:
          • Jens Voigt
      • Stockholm, Sweden
        • Not yet recruiting
        • Danderyd Hospital
        • Contact:
          • Reidar Winter
      • Cardiff, United Kingdom
        • Recruiting
        • University Hospital Wales
        • Contact:
          • Alan G Fraser
        • Principal Investigator:
          • Alan G Fraser
      • Cottingham, United Kingdom
        • Not yet recruiting
        • Castle Hill Hospital
        • Contact:
          • Imran D Sunderji
        • Principal Investigator:
          • Imran D Sunderji

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 89 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Secondary care referrals

Description

Inclusion Criteria:

  • Chest pain, chest pain equivalent

Exclusion Criteria:

  • acute coronary syndrome with elevated troponin, severe heart valve disease, uncontrolled hypertension (resting SBP >200mmHg), cardiomyopathy, contraindication to dobutamine, pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Control
Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
Deformation parameters derived using myocardial velocity imaging or speckle tracking
Deformation imaging
Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
Deformation parameters derived using myocardial velocity imaging or speckle tracking
High p(CAD)
Intermediate-to-high probability of significant epicardial coronary disease (>50%).
Deformation parameters derived using myocardial velocity imaging or speckle tracking
All comers
Probability of severe disease ranging from 15 to 85%.
Deformation parameters derived using myocardial velocity imaging or speckle tracking

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic accuracy of quantitative measures of dobutamine stress echocardiography
Time Frame: 18 months
Echocardiographic measurements of segmental myocardial velocity, strain, strain rate and wall motion scoring referenced against measurements derived from coronary angiography.
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lowest dose of dobutamine to provoke measurable marker of inducible myocardial ischaemia
Time Frame: 18 months
Using modelling techniques applied predict lowest dose of dobutamine to maintain diagnostic accuracy
18 months
Diagnostic accuracy of using machine learning to interpret multiparametric and multidimensional datasets to diagnose myocardial ischaemia
Time Frame: 18 months
Use modelling to combine pre-test probabilities (based on risk factors such as age), physiological factors (e.g., heart rate) that are associated with longitudinal function and data derived throughout the cardiac cycle (i.e., based on analysis of velocity or strain curves and not just a single value like peak velocity or strain).
18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alan G Fraser, University Hospital Wales

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 21, 2016

Primary Completion (Anticipated)

October 31, 2020

Study Completion (Anticipated)

October 31, 2021

Study Registration Dates

First Submitted

August 17, 2018

First Submitted That Met QC Criteria

September 2, 2018

First Posted (Actual)

September 6, 2018

Study Record Updates

Last Update Posted (Actual)

September 6, 2018

Last Update Submitted That Met QC Criteria

September 2, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ischemia, Myocardial

Clinical Trials on Deformation imaging

3
Subscribe